Abstract:Post‐translational modifications (PTMs) of RNA‐modifying proteins, such as METTL3 and METTL14, modulate their activity and interactions, impacting transcription, signaling pathways, and immune responses. These processes are crucial in driving cancer progression, immune evasion, and pathogen responses, making PTMs of RNA modifiers potential therapeutic targets for clinical intervention in various diseases. This underscores their significance in both cellular dynamics and disease treatment strategies. RNA‐modifying proteins, classified as "writers," "erasers," and "readers," dynamically modulate RNA by adding, removing, or interpreting chemical groups, thereby influencing RNA stability, functionality, and interactions. To date, over 170 distinct RNA chemical modifications and more than 100 RNA‐modifying enzymes have been identified, with ongoing research expanding these numbers. Although significant progress has been made in understanding RNA modification, the regulatory mechanisms that govern RNA‐modifying proteins themselves remain insufficiently explored. Post‐translational modifications (PTMs) such as phosphorylation, ubiquitination, and acetylation are crucial in modulating the function and behavior of these proteins. However, the full extent of PTM influence on RNA‐modifying proteins and their role in disease development remains to be fully elucidated. This review addresses these gaps by offering a comprehensive analysis of the roles PTMs play in regulating RNA‐modifying proteins. Mechanistic insights are provided into how these modifications alter biological processes, contribute to cellular function, and drive disease progression. In addition, the current research landscape is examined, highlighting the therapeutic potential of targeting PTMs on RNA‐modifying proteins for precision medicine. By advancing understanding of these regulatory networks, this review seeks to facilitate the development of more effective therapeutic strategies and inspire future research in the critical area of PTMs in RNA‐modifying proteins.

Functional roles of ADP-ribosylation writers, readers and erasers

ADP-ribose hydrolases: biological functions and potential therapeutic targets

Uncovering the Invisible: Mono-ADP-ribosylation Moved into the Spotlight

[Poly Adenosine Diphosphate-Ribosylation and Neurodegenerative Diseases].

ADP-ribosylation of RNA and DNA: from in vitro characterization to in vivo function

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

The quest to identify ADP-ribosylation readers: methodological advances

ADP-ribosylation: from molecular mechanisms to human disease

Beyond protein modification: the rise of non-canonical ADP-ribosylation

General ADP-Ribosylation Mechanism Based on the Structure of ADP-Ribosyltransferase-Substrate Complexes

Poly‐ADP‐ribosylation dynamics, signaling, and analysis

ADP-ribosylation of RNA in mammalian cells is mediated by TRPT1 and multiple PARPs

The FHA and BRCT Domains Recognize ADP-ribosylation During DNA Damage Response.

A ribose-functionalized NAD+ with versatile activity for ADP-ribosylation

Mono-ADP-ribosylation, a MARylationmultifaced modification of protein, DNA and RNA: characterizations, functions and mechanisms

Post‐Translational Modifications of RNA‐Modifying Proteins in Cellular Dynamics and Disease Progression

Structural and biochemical insights into the molecular mechanism of TRPT1 for nucleic acid ADP-ribosylation

ADP-ribosylation of DNA and RNA

N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction.

Mono‐ADP‐ribosylation of peptides: an overview of synthetic and chemoenzymatic methodologies

The expanding universe of PARP1-mediated molecular and therapeutic mechanisms